Cirius Therapeutics to Highlight Cardiometabolic Benefits of CIR-0602K at Global Cardiovascular Clinical Trialists (CVCT) Forum 2025

Data from Phase 2 Trials Underscore Cardioprotective Potential

GRAND RAPIDS, Mich., Dec. 9, 2025 /PRNewswire/ — Cirius Therapeutics, Inc., a developer of innovative therapies for…